RVX 100

Drug Profile

RVX 100

Alternative Names: RVX-100

Latest Information Update: 17 May 2010

Price : $50

At a glance

  • Originator Revogenex
  • Class Irritable bowel syndrome therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Suspended Irritable bowel syndrome

Most Recent Events

  • 17 May 2010 Suspended - Phase-II for Irritable bowel syndrome in USA (unspecified route)
  • 20 Apr 2010 Phase-II clinical trials in Irritable bowel syndrome in USA (unspecified route)
  • 25 Feb 2010 Investigation in Irritable bowel syndrome in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top